Stock KPL6 KWALITY PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kwality Pharmaceuticals Limited

Equities

KPL6

INE552U01010

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:19:01 2024-04-26 am EDT 		5-day change 1st Jan Change
507 INR +1.36% Intraday chart for Kwality Pharmaceuticals Limited +13.03% +26.81%
Feb. 06 Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 425.4 384.4 265.1 581.1 6,018 3,191
Enterprise Value (EV) 1 626.7 617.4 566 890.9 6,429 4,020
P/E ratio 9.36 x 5.09 x 3.19 x 3.84 x 5.02 x 16.5 x
Yield - - - - - -
Capitalization / Revenue 0.31 x 0.23 x 0.19 x 0.22 x 1.31 x 1.27 x
EV / Revenue 0.45 x 0.37 x 0.4 x 0.34 x 1.4 x 1.6 x
EV / EBITDA 5.13 x 3.83 x 3.26 x 2.95 x 3.71 x 6.52 x
EV / FCF -10.2 x -16.4 x -2.73 x -31 x -28.5 x -15.5 x
FCF Yield -9.85% -6.1% -36.7% -3.22% -3.51% -6.43%
Price to Book 1.43 x 1.03 x 0.58 x 0.95 x 3.32 x 1.59 x
Nbr of stocks (in thousands) 10,376 10,376 10,376 10,376 10,376 10,376
Reference price 2 41.00 37.05 25.55 56.00 580.0 307.6
Announcement Date 10/15/18 9/6/19 11/6/20 9/7/21 9/7/22 9/8/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 1,380 1,667 1,425 2,631 4,579 2,510
EBITDA 1 122.2 161.2 173.7 301.8 1,735 616.4
EBIT 1 92.4 130 129.3 236.9 1,628 466.8
Operating Margin 6.7% 7.8% 9.08% 9.01% 35.55% 18.6%
Earnings before Tax (EBT) 1 72.96 109.1 109.2 212.7 1,616 255.7
Net income 1 45.46 75.52 83.17 151.5 1,200 193.7
Net margin 3.3% 4.53% 5.84% 5.76% 26.21% 7.72%
EPS 2 4.381 7.279 8.016 14.60 115.6 18.67
Free Cash Flow 1 -61.73 -37.66 -207.5 -28.71 -225.9 -258.7
FCF margin -4.47% -2.26% -14.57% -1.09% -4.93% -10.31%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 10/15/18 9/6/19 11/6/20 9/7/21 9/7/22 9/8/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 201 233 301 310 411 829
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.647 x 1.446 x 1.733 x 1.026 x 0.2367 x 1.345 x
Free Cash Flow 1 -61.7 -37.7 -208 -28.7 -226 -259
ROE (net income / shareholders' equity) 16.4% 23.2% 20.2% 28.4% 100% 10.2%
ROA (Net income/ Total Assets) 6.91% 8.06% 6.79% 9.91% 40.1% 8.4%
Assets 1 657.8 937.1 1,225 1,529 2,989 2,305
Book Value Per Share 2 28.70 35.90 44.30 58.90 175.0 193.0
Cash Flow per Share 2 1.550 1.350 1.480 5.600 12.50 2.960
Capex 1 63.5 118 208 234 552 477
Capex / Sales 4.61% 7.09% 14.59% 8.9% 12.05% 18.99%
Announcement Date 10/15/18 9/6/19 11/6/20 9/7/21 9/7/22 9/8/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KWALITY PHARMACEUTICALS LIMITED Stock Kwality Pharmaceuticals Limited
+26.81% 63.08M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. KPL6 Stock
  4. Financials Kwality Pharmaceuticals Limited